Rapport’s work revolves around “RAPs,” or receptor-associated proteins. These proteins, unlike other kinds, are local to specific areas of the brain and central nervous system. By targeting RAPs, Rapport believes it can create precision drugs that are either more effective or safer than other treatment options.
The company’s most advanced program has already entered human testing as a potential therapy for drug-resistant seizure disorders. When Rapport, with offices in Boston and San Diego, launched in March with $100 million from a Series A financing round, its newly appointed CEO Abraham Ceesay said the money would help to get that lead program to the point where it had “proof-of-concept” data.
